Impact of Dietary Phosphate Excess on Exercise Capacity and Visceral Adiposity
Recruiting · NCT05147909 · Interventional (participants receive a specific treatment) · Lead sponsor: University of Texas Southwestern Medical Center
View the official record on ClinicalTrials.gov →Interventions studied
Sodium ChlorideSodium Phosphate
What this trial is about
Studies in mice demonstrated that dietary phosphate (Pi) loading that mimic the level of US adult consumption leads to reduced spontaneous locomotor activity, exercise capacity, and reduced resting metabolic rate when in normal mice by impairing skeletal muscle mitochondrial function and fat oxidation. However, relevance of this findings in humans remains unknown.
Who can take part
Age range
18 Years to 80 Years
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- The randomized crossover trial will be performed in on otherwise healthy subjects without diabetes mellitus, chronic kidney disease (CKD), preexisting cardiovascular disease or treatment with any vasoactive agent that might alter cardiovascular responses to exercise.
Exclusion criteria
- history of cardiopulmonary disease or chronic kidney disease,
- treatment with antihypertensive medications,
- estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73m2, (4) diabetes mellitus or other systemic illness,
- pregnancy, (6) hypersensitivity to sodium phosphate, (7) any history of substance abuse or current cigarette use, (8) any history of psychiatric illness, (9) history of active malignancy, (10) serum phosphorus \< 2.4 or \> 4.5 mg/dL.
Where it is running
1 location listed across 1 US state.
- University of Texas Southwestern - Dallas, Texas, United States